The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review
Abstract
Background: Varying degrees of cortical amyloid deposition are reported in the setting of Parkinsonism with cognitive impairment. We performed a systematic review to estimate the prevalence of Alzheimer disease (AD) range cortical amyloid deposition among patients with Parkinson's disease with dementia (PDD), Parkinson's disease with mild cognitive impairment (PD‐MCI) and dementia with Lewy bodies (DLB). We included amyloid positron emission tomography (PET) imaging studies using Pittsburgh Compound B (PiB). Methods: We searched the databases Ovid MEDLINE, PubMed, Embase, Scopus, and Web of Science for articles pertaining to amyloid imaging in Parkinsonism and impaired cognition. We identified 11 articles using PiB imaging to quantify cortical amyloid. We used the metan module in Stata, version 11.0, to calculate point prevalence estimates of patients with “PiB‐positive” studies, that is, patients showing AD range cortical Aβ‐amyloid deposition. Heterogeneity was assessed. A scatterplot was used to assess publication bias. Results: Overall pooled prevalence of “PiB‐positive” studies across all three entities along the spectrum of Parkinson's disease and impaired cognition (specifically PDD, PD‐MCI, and DLB) was 0.41 (95% confidence interval [CI], 0.24‐0.57). Prevalence of “PiB‐positive” studies was 0.68 (95% CI, 0.55‐0.82) in the DLB group, 0.34 (95% CI, 0.13‐0.56) in the PDD group, and 0.05 (95% CI, −0.07‐0.17) in the PD‐MCI group. Conclusions: Substantial variability occurs in the prevalence of “PiB‐positive” studies in subjects with Parkinsonism and cognitive impairment. Higher prevalence of PiB‐positive studies was encountered among subjects with DLB as opposed to subjects with PDD. The PD‐MCI subjects showed overall lower prevalence of PiB‐positive studies than reported findings in non–PD‐related MCI. © 2015 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Up to 80% of individuals with dementia with Lewy bodies exhibit amyloid-β pathology as well as α-synuclein pathology.
“Notably, up to 80% of individuals with dementia with Lewy bodies exhibit amyloid-β pathology as well as α-synuclein pathology [167].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [167]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · cited 4×
“Movement Disorders, Vol. 30, No. 7, 2015 931 amyloid deposition plateaus at high levels before onset of cognitive impairment in AD.39 Against this background, our findings in synucleinopathy subjects are significantly divergent.”
BackgroundInfluentialImaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602
Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377 · cited 1×
“Recent data suggest that changes in neurotransmitter systems influence amyloid precursor protein metabolism significantly.(41,42) Our study has limitations.”
BackgroundIndicators of amyloid burden in a population-based study of cognitively normal elderly
Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., Geda, Y. E., Swenson-Dravis, D. M., Boeve, B. F., Senjem, M. L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e2696 · Cited by 163
Flagged first, then by citations
Research works printed but not linked: 35
- 10.1007/s00401-008-0344-8 · DOI
- 10.1001/archneur.60.3.387 · DOI
- 10.1017/S0033291713002213 · DOI
- 10.1017/S0033291713000494 · DOI
- 10.1159/000197890 · DOI
- 10.1212/01.wnl.0000256715.13907.d3 · DOI · Paper page
- 10.1007/s00401-011-0852-9 · DOI
- 10.1016/S1353-8020(08)70005-1 · DOI
- 10.1002/ana.20009 · DOI · Paper page
- 10.1093/brain/awr031 · DOI
- 10.1097/NEN.0b013e31816362aa · DOI
- 10.1093/brain/awr089 · DOI
- 10.1016/j.neurobiolaging.2011.09.024 · DOI
- 10.1016/j.nbd.2008.12.008 · DOI
- 10.1002/mds.23393 · DOI
- 10.1002/mds.25286 · DOI
- 10.1002/mds.25048 · DOI
- 10.1212/WNL.0b013e31827b1a07 · DOI
- 10.1136/jnnp.2007.127878 · DOI
- 10.1016/j.parkreldis.2010.08.021 · DOI
- 10.1212/WNL.0b013e3182698d4a · DOI
- 10.1186/1471-2288-3-25 · DOI · Paper page
- 10.1001/archneur.1993.00540020018011 · DOI
- 10.1111/j.1600-0404.1994.tb01674.x · DOI
- American Psychiatric Association, Diagnostic criteria from DSM‐IV‐TR. 2000, 370
- 10.1002/sim.1186 · DOI · Paper page
- 10.2967/jnumed.111.089730 · DOI
- 10.1001/archneurol.2011.153 · DOI · Paper page
- 10.1001/archneurol.2010.357 · DOI
- 10.1212/01.wnl.0000228230.26044.a4 · DOI · Paper page
- 10.1016/S1474-4422(12)70227-2 · DOI
- 10.1016/S1474-4422(14)70194-2 · DOI · Paper page
- 10.1002/mds.21956 · DOI
- 10.1001/archneurol.2012.764 · DOI
- Scheinin NM, 2014, Cortical 11C‐PIB uptake is associated with age, APOE genotype, and gender in “healthy aging.”, J Alzheimers Dis, 41, 193, 10.3233/JAD-132783 · DOI
Cited by
Sorted by citations
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationCognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
Serotonin, β‐amyloid, and cognition in Parkinson disease
Kotagal, V., Spino, C., Bohnen, N. I., Koeppe, R., & Albin, R. L. (2018) · Annals of Neurology · doi:10.1002/ana.25236 · Cited by 64
Self-citationDementia with Lewy bodies: Challenges in the diagnosis and management
Chin, K. S., Teodorczuk, A., & Watson, R. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419835029 · Cited by 63
Lizama, B. N., Kahle, J., Catalano, S. M., Caggiano, A. O., Grundman, M., & Hamby, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076251 · Cited by 54
Dysfunction of serotonergic neurons in Parkinson’s disease and dyskinesia
Vegas-Suarez, S., Paredes-Rodriguez, E., Aristieta, A., Lafuente, J. V., Miguelez, C., & Ugedo, L. (2019) · International Review of Neurobiology · doi:10.1016/bs.irn.2019.06.013 · Cited by 26
Metadata
- Authors
- Petrou, M., Dwamena, B. A., Foerster, B. R., MacEachern, M. P., Bohnen, N. I., Müller, M. L., Albin, R. L., & Frey, K. A.
- Affiliations
- Department of Radiology University of Michigan Ann Arbor Michigan USA
- Taubman Health Sciences Library University of Michigan Ann Arbor Michigan USA
- Veterans Administration Healthcare System Ann Arbor Michigan USA
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2015-04-16
- Volume
- 30
- Issue
- 7
- Pages
- 928-935
- ISSN
- 0885-3185
- 1531-8257
- PMC
- PMC4478091
- Cited by
- 208
- References
- 8
- Language
- en
- Funders
- USPHS (P50NS091856)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
